Sandoz to Launch Hyrimoz (biosimilar- adalimumab) in Canada

Share this
Sandoz to Launch Hyrimoz (biosimilar- adalimumab) in Canada

Sandoz to Launch Hyrimoz (biosimilar- adalimumab) in Canada


  • Health Canada has authorized Hyrimoz on Nov 4- 2020 for marketing in Canada. Hyrimoz has been approved for use in all same indications as reference Humira- including rheumatology- gastroenterology and dermatology
  • A patient support program will be available to patients treated with Hyrimoz providing guidance with reimbursement navigation- financial assistance- administrative support & education for patients
  • Hyrimoz is a fully human TNF blocker. The notice of compliance has been issued for 3 SC dosage forms: 40 mg/0.8 mL & 20 mg/0.4mL in prefilled syringe- 40 mg/0.8 mL in autoinjector

 ­ Ref: GlobeNewswire | Image: PRNewswire

Click here to­ read the full press release 


Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions